GlassScriptPhysician profile
Wilson Evans Kemp
NPI 1861430621
$2,664.34
in general payments reported to CMS, 2019-2025
29 companies · $296 in 2025
The $296 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $17.37 · 2022: $41.54 · 2023: $856 · 2024: $1,017 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,169.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $533.98 | 2019-2025 | Navitor |
| Lilly USA, LLC | $347.13 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $227.00 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.27 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $201.32 | 2019-2025 | |
| Amgen INC. | $134.58 | 2023-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $113.16 | 2022-2023 | |
| Boston Scientific Corporation | $107.70 | 2024-2025 | Watchman Flx |
| Pfizer INC. | $101.66 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.12 | 2024 | Caplyta |
| Glaxosmithkline, LLC. | $72.69 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Philips North America LLC | $59.57 | 2023 | |
| Heartflow, INC. | $48.83 | 2023-2024 | Ffrct |
| Bayer Healthcare Pharmaceuticals INC. | $46.26 | 2023 | |
| Idorsia Pharmaceuticals US INC | $44.20 | 2023 | Quviviq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $37.13 | 2023-2024 | Nuzyra |
| Janssen Pharmaceuticals, INC | $34.59 | 2024 | Xarelto |
| Cvrx, INC. | $30.90 | 2023 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $29.39 | 2023-2024 | Verquvo, Belsomra |
| E.R. Squibb & Sons, L.L.C. | $28.47 | 2025 | Camzyos |
| Corium, LLC | $26.06 | 2023 | Azstarys |
| Dexcom, INC. | $24.18 | 2024 | Dexcom G6 Transmitter |
| Kerecis Limited | $18.65 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.84 | 2023 | Lifevest |
| Astellas Pharma US INC | $17.37 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $16.86 | 2024 | Austedo Xr |
| Exact Sciences Corporation | $14.97 | 2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $14.73 | 2023 | Farxiga |
| Viatris Specialty LLC | $13.73 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilson Kemp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.